ClinicalTrials.gg
CompletedNCT05246137Updated Nov 17, 2026

A Phase III Trial to Assess the Safety and Immunogenicity of a HIPRA's Candidate Booster Vaccination Against COVID-19.

A Phase 3 interventional study of COVID-19 Vaccine 40 ug/dose in SARS-CoV-2 Infection, sponsored by Hipra Scientific, S.L.U. Completed at 18 sites in 2 countries. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Hipra Scientific, S.L.U · Phase 3, Interventional, and Prevention

How we know

Updated Nov 17, 2026Primary completion movedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,661
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 401 studies in COVID-19 with a site in Spain — 25 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · Spain.

Enrollment
19th of 254
2,661 · median 132
Started
2022
with 47 others
Phase 3
65 of 401
6 open now
Registered
301st of 401
by date
Lead sponsor
7 of 401
Hipra Scientific, S.L.U

Among the 401 studies in COVID-19 with a site in Spain, this one is the 19th largest by enrollment of the 254 interventional ones that give a count, is one of 48 that started in 2022, is one of 65 in phase 3, and was the 301st registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

25 of the 401 studies in COVID-19 with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 16 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in COVID-19 with a site in Spain, or all of them as a file.
02

Study summary

This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adult subjects vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine.

Read the detailed description

This is a phase III clinical study to assess the safety, tolerability and immunogenicity of PHH-1V as a booster dose in healthy adults vaccinated against COVID-19 with the Comirnaty, Spikevax, Vaxevria or Janssen vaccine at least 91 days before day 0. All the participants will receive a booster dose of the HIPRA's COVID-19 Vaccine and will be followed for 26 weeks or 52 weeks if they participate in the safety cohort, or the immunogenicity cohort, respectively.

03

Conditions studied

  • SARS-CoV-2 Infection

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, ≥ 16 years old at Day 0.
  • Willing to provide consent indicating that she or he understands the purpose and potential risks and is willing and able to participate in the study and comply with all the study requirements and procedures.
  • Have a recognized primary vaccination scheme recognized by the authorities with Comirnaty, Spikevax, Vaxevria or Janssen at least 91 days and preferably a maximum of 240 days before Day 0.
  • If having an underlying illnesses must be stable and well-controlled according to the investigator judgment.
  • Participant is willing to avoid receiving (licensed) within 4 weeks before screening or after receiving any study vaccine, or other not live vaccines (licensed) within 14 days before and after receiving any study vaccine.
  • Participant agrees not to donate blood, blood products and bone marrow at least 3 months before and after vaccination.
  • Female participant of must have a negative pregnancy test on the on Day 0 prior to vaccination.
  • Female participant of childbearing potential must use any acceptable method that should be started on day 0 and until 8 weeks after vaccination (hormonal contraception: oral, injectable or transdermal patch, intrauterine device, vasectomized partner, sexual abstinence or condom).
  • Male participants must use any acceptable contraceptive method that should be started on day 0 and until 8 weeks after vaccination (vasectomized participants, condom, sexual abstinence).
  • Male participants must refrain from donating sperm for at least 28 days after day 0.

Exclusion criteria

Exclusion Criteria:

  • History of anaphylaxis to any prior vaccine.
  • Previous severe SARS-CoV-2 infections that required >24 hous of hospitalisation.
  • Participant received or plans to receive within 4 weeks before and after day 0; or other not live vaccines within 14 days before and after day 0.
  • Pregnancy or breast-feeding at screening or Day 0 or willingness/intention to become pregnant during the study.
  • Having a acute illness or fever (temperature ≥38º C (100.4ºF)) at screening or within 48 hours prior to Day 0.
  • Participant had a surgery requiring hospitalization before vaccination and he/she has not received the hospital discharge at day 0; or has a surgery requiring hospitalization planned within 12 weeks after study vaccine administration.
  • Having any active even if under treatment except for non-melanoma skin cancer, uterine cervical carcinoma, anal carcinoma, localized prostate cancer.
  • Having ongoing severe and non-stable psychiatric condition likely to affect participation in the study.
  • Having problematic or risk use of substances including alcohol that can compromise the study follow-up.
  • Having a bleeding disorder or has any condition that in the opinion of the investigator contraindicates intramuscular injections.
  • Having abnormal function of the immune system, except stable clinical conditions like controlled .
  • Having clinically significant and unstable cardiovascular, respiratory, hepatic, neurological, gastrointestinal, renal, or any other medical disorder judged by the investigator within 3 months before screening.
  • Chronic or recurrent administration of systemic medication.
  • Having received immunoglobulins and/or blood-derived products 12 weeks prior vaccination (Day 0) or expects to receive them during the study.
  • Having received any immunotherapy (monoclonal antibodies, plasma) aimed to prevent or treat COVID-19 within 90 days before day 0.
  • Participation in any research involving an product (drug, biologic, device) within 12 weeks prior to vaccination and during the study.
  • Participant has donated ≥ 450ml of blood products within 12 weeks before screening.
  • Participant has any medical condition and/or finding that in the investigator opinion might increase participant risks, interfere with the study or impair interpretation of study data.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,661 participants (actual)

Study arms

  • Experimental
    Experimental: COVID-19 Vaccine HIPRA 40 ug/dose

    COVID-19 Vaccine HIPRA, where subjects will receive one intramuscular injection of COVID-19 vaccine developed by HIPRA

    Biological: COVID-19 Vaccine 40 ug/dose

Interventions

  • BiologicalCOVID-19 Vaccine 40 ug/dose

    Intramuscular injection of 0,5 ml with 40 ug of recombinant PHH-1V

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (Safety and tolerability)

    Number, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination.

    Time frame: Day 7

  2. Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) (AEs)

    Number, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through Day 28 after vaccination

    Time frame: Day 28

  3. Incidence of Serious Adverse Events (Safety and tolerability) (SAE)

    Number and percentage of serious adverse events (SAEs) through the end of the study.

    Time frame: Day 365

  4. Incidence of Special Interest Adverse Events (Safety and tolerability) (AESI).

    Number and percentage of adverse event of special interest (AESI) through the end of the study.

    Time frame: Day 365

  5. Incidence of Medically Attended Adverse Events (Safety and tolerability) (MAAEs)

    Number and percentage of medically attended adverse events (MAAE) related to study vaccine through the end of the study.

    Time frame: Day 365

  6. Incidence of Adverse Events in laboratory parameters (Safety and tolerability)

    Grade 3 and 4 changes from baseline in safety laboratory parameters at Days 14, 91 and 182 after vaccination. through the end of the study.

    Time frame: Day 365

Secondary outcomes

  1. Changes in the immunogenicity measured by pseudovirus neutralisation

    Neutralisation titre against Wuhan and Omicron strains, and any other relevant VOC in the epidemiologic moment, measured as inhibitory concentration 50 (IC50) by a pseudovirion-based neutralisation assay (PBNA) and reported as reciprocal concentration for each individual sample and geometric mean titre (GMT) for descriptive statistics analysis at Baseline and at Days 14, 91, 182 and 365.

    Time frame: Day 365

  2. Changes in the immunogenicity measured by pseudovirus neutralisation

    The geometric mean fold rise (GMFR) in neutralising antibody titre from baseline to Day 14.

    Time frame: Day 14

  3. Changes in the immunogenicity measured by means of total antibody against RBD

    Binding antibodies titre measured for each individual sample and GMT for descriptive statistics analysis at Baseline and Days 14, 91, 182 and 365.

    Time frame: Day 365

  4. Changes in the immunogenicity measured by means of total antibody against RBD.

    The geometric mean fold rise (GMFR) in binding antibody titre from baseline to Day 14.

    Time frame: Day 14

  5. Changes in the immunogenicity measured by means of total antibody against RBD

    The percentage of subjects that after the booster dose have a ≥4-fold change in binding antibodies titre from Baseline to Day 14.

    Time frame: Day 14

Other outcomes

  1. To assess number of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster.

    Number and percentage of subjects with SARS-CoV-2 infections ≥14 days after PHH-1V booster according to COVID-19 infection criteria throughout the study duration.

    Time frame: Day 365

  2. To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V. SARS-CoV-2 infections ≥14 days after PHH-1V booster.

    Number and percentage of COVID-19 severe infections ≥14 days after PHH-1V booster and through the end of the study.

    Time frame: Day 365

  3. To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V and hospital admissions SARS-CoV-2 infections ≥14 days after PHH-1V booster.

    Number and percentage of hospital admissions associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study.

    Time frame: Day 365

  4. To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V in ICU. SARS-CoV-2 infections ≥14 days after PHH-1V booster.

    Number and percentage of intensive care unit (ICU) admissions associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study.

    Time frame: Day 365

  5. To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V receiving noninvasive ventilation. SARS-CoV-2 infections ≥14 days after PHH-1V booster.

    Number and percentage of noninvasive ventilation administration associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study.

    Time frame: Day 365

  6. To assess number of COVID-19 severe infections ≥14 days after receiving PHH-1V causing death.

    Number and percentage of deaths associated with COVID-19 ≥14 days after PHH-1V booster and through the end of the study.

    Time frame: Day 365

  7. To evaluate T-cell mediated responses against the SARS-CoV-2 S glycoprotein at Baseline and Day 14 in subjects who have received two doses of Vaxzevria vaccine and PHH-1V as a booster..

    T-cell-mediated response to the SARS-CoV-2 S protein as measured by whole peripheral blood mononuclear cell (PBMC) stimulation by enzyme-linked immune absorbent spot (ELISpot) at Baseline and at Day 14. This analysis will be performed in 30 subjects.

    Time frame: Day 14

  8. To assess Th-1/Th-2 T-cell mediated responses against S protein at Baseline and Day 14 in subjects who have received two doses of Vaxzevria vaccine and PHH-1V as a booster.

    CD4+/CD8+ T-cell response to the SARS-CoV-2 S protein as measured by in vitro PBMC stimulation by cytokine staining assays at Baseline and at Day 14. This analysis will be performed in 30 subjects.

    Time frame: Day 14

07

Study locations

18 sites
  • Hospital de Niguarda
    Milan, Milano 20162, Italy
  • Hospital Germans Trias I Pujol
    Badalona, BARCELONA 08916, Spain
  • Hospital HM Delfos
    Barcelona, Barcelona 08023, Spain
  • Hospital Quironsalud Barcelona
    Barcelona, Barcelona 08023, Spain
  • Hospital Vall Hebron
    Barcelona, BARCELONA 08035, Spain
  • Hospital de Mollet
    Mollet del Vallès, Barcelona 08100, Spain
  • Hospital Universitari Dr. Josep Trueta
    Girona, Girona 17007, Spain
  • Hospital Gregorio Marañón
    Madrid, Madrid 28007, Spain
  • Hospital Universitario La Paz
    Madrid, Madrid 28046, Spain
  • Hospital HM Sanchinarro
    Madrid, Madrid 28050, Spain
  • Hospital Quironsalud Madrid
    Madrid, Madrid 28223, Spain
  • Hospital HM Montepríncipe
    Madrid, Madrid 28660, Spain
  • Hospital Principe de Asturias
    Meco, Madrid 28805, Spain
  • Hospital HM Puerta del Sur
    Móstoles, Madrid 28938, Spain
  • Hospital Regional Universitario de Málaga
    Málaga, Málaga 29010, Spain
  • Hospital Clinic de Barcelona
    Barcelona, Spain 17170, Spain
  • Hospital Clínico de Valencia
    Valencia, Valencia 46010, Spain
  • Hospital de Cruces
    Barakaldo, VIZCAYA 48903, Spain
08

References and documents

Publications

  • Moros A, Prenafeta A, Barreiro A, Perozo E, Fernandez A, Canete M, Gonzalez L, Garriga C, Pradenas E, Marfil S, Blanco J, Cebollada Rica P, Sistere-Oro M, Meyerhans A, Prat Cabanas T, March R, Ferrer L. Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate. Vaccine. 2023 Aug 7;41(35):5072-5078. doi: 10.1016/j.vaccine.2023.07.008. Epub 2023 Jul 16. PubMed 37460353 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Mar 2023, 13 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 13 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

Primary completion moved once since we started tracking on Sep 25, 2026: Mar 2022 → Mar 2023, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2022
First posted
Feb 18, 2022
StartActual
Feb 3, 2022
Primary completionActual
Mar 3, 2023was Mar 2022
CompletionActual
Mar 3, 2023
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
16 sites added, 16 sites removed
Show 16 added (15 Spain, 1 Italy)
  • Hospital de Niguarda · Milan, Italy
  • Hospital Germans Trias I Pujol · Badalona, Spain
  • Hospital HM Delfos · Barcelona, Spain
  • Hospital Quironsalud Barcelona · Barcelona, Spain
  • Hospital Vall Hebron · Barcelona, Spain
  • Hospital de Mollet · Mollet del Vallès, Spain
  • Hospital Universitari Dr. Josep Trueta · Girona, Spain
  • Hospital Gregorio Marañón · Madrid, Spain
  • Hospital Universitario La Paz · Madrid, Spain
  • Hospital HM Sanchinarro · Madrid, Spain
  • Hospital Quironsalud Madrid · Madrid, Spain
  • Hospital HM Montepríncipe · Madrid, Spain
  • Hospital Regional Universitario de Málaga · Málaga, Spain
  • Hospital Clinic de Barcelona · Barcelona, Spain
  • Hospital Clínico de Valencia · Valencia, Spain
  • Hospital de Cruces · Barakaldo, Spain
Show 16 removed
  • Hospital de Niguarda · Milano, Italy
  • Hospital Germans Trias I Pujol · Badalona, Spain
  • Hospital de Mollet · Mollet Del Vallès, Spain
  • Hospital de Cruces · Barakaldo, Spain
  • Hospital HM Delfos · Barcelona, Spain
  • Hospital Quironsalud Barcelona · Barcelona, Spain
  • Hospital Vall Hebron · Barcelona, Spain
  • Hospital Clinic de Barcelona · Barcelona, Spain
  • Hospital Universitari Dr. Josep Trueta · Girona, Spain
  • Hospital Gregorio Marañón · Madrid, Spain
  • Hospital Universitario La Paz · Madrid, Spain
  • Hospital HM Sanchinarro · Madrid, Spain
  • Hospital Quironsalud Madrid · Madrid, Spain
  • Hospital HM Montepríncipe · Madrid, Spain
  • Hospital Regional Universitario de Málaga · Málaga, Spain
  • Hospital Clínico de Valencia · Valencia, Spain
Nov 17, 2026
Primary completion
Mar 3, 2022→Mar 3, 2023
Nov 17, 2026
Enrollment
2646→2661
Nov 17, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 37460353 ↗
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 37460353 ↗
    16 sites added, 16 sites removed
    Show 16 added (15 Spain, 1 Italy)
    • Hospital de Niguarda · Milan, Italy
    • Hospital Germans Trias I Pujol · Badalona, Spain
    • Hospital HM Delfos · Barcelona, Spain
    • Hospital Quironsalud Barcelona · Barcelona, Spain
    • Hospital Vall Hebron · Barcelona, Spain
    • Hospital de Mollet · Mollet del Vallès, Spain
    • Hospital Universitari Dr. Josep Trueta · Girona, Spain
    • Hospital Gregorio Marañón · Madrid, Spain
    • Hospital Universitario La Paz · Madrid, Spain
    • Hospital HM Sanchinarro · Madrid, Spain
    • Hospital Quironsalud Madrid · Madrid, Spain
    • Hospital HM Montepríncipe · Madrid, Spain
    • Hospital Regional Universitario de Málaga · Málaga, Spain
    • Hospital Clinic de Barcelona · Barcelona, Spain
    • Hospital Clínico de Valencia · Valencia, Spain
    • Hospital de Cruces · Barakaldo, Spain
    Show 16 removed
    • Hospital de Niguarda · Milano, Italy
    • Hospital Germans Trias I Pujol · Badalona, Spain
    • Hospital de Mollet · Mollet Del Vallès, Spain
    • Hospital de Cruces · Barakaldo, Spain
    • Hospital HM Delfos · Barcelona, Spain
    • Hospital Quironsalud Barcelona · Barcelona, Spain
    • Hospital Vall Hebron · Barcelona, Spain
    • Hospital Clinic de Barcelona · Barcelona, Spain
    • Hospital Universitari Dr. Josep Trueta · Girona, Spain
    • Hospital Gregorio Marañón · Madrid, Spain
    • Hospital Universitario La Paz · Madrid, Spain
    • Hospital HM Sanchinarro · Madrid, Spain
    • Hospital Quironsalud Madrid · Madrid, Spain
    • Hospital HM Montepríncipe · Madrid, Spain
    • Hospital Regional Universitario de Málaga · Málaga, Spain
    • Hospital Clínico de Valencia · Valencia, Spain
    Primary completion Mar 3, 2022→Mar 3, 2023
    Enrollment 2646→2661
    + 3 other changes: verification date, conditions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05246137
Lead sponsor
Hipra Scientific, S.L.U
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
Feb 3, 2022
Primary completion
Mar 3, 2023
Completion
Mar 3, 2023
Last update
Nov 17, 2026

Study contacts

Teresa Prat
study director · HIPRA SICENTIFIC S.L.U

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion